GlassScriptPhysician profile
Dailan Zhang
NPI 1033827993
$2,067.15
in general payments reported to CMS, 2019-2025
25 companies · $15.55 in 2025
The $15.55 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,323 · 2024: $729 · 2025: $15.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $239.53 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $170.90 | 2023-2024 | Austedo Xr, Austedo |
| Abbvie INC. | $165.21 | 2023-2024 | |
| Sk Life Science, INC. | $142.52 | 2023-2024 | |
| Pfizer INC. | $136.13 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $132.50 | 2023 | Tarpeyo |
| Ucb, INC. | $116.20 | 2023-2024 | Briviact |
| Lundbeck LLC | $113.91 | 2023-2024 | Vyepti, Rexulti |
| Merck Sharp & Dohme LLC | $110.42 | 2024 | Keytruda |
| Neurocrine Biosciences, INC. | $107.06 | 2023-2024 | Ingrezza, Ongentys |
| Astrazeneca Pharmaceuticals LP | $103.37 | 2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $78.13 | 2023-2024 | Rytary |
| Lilly USA, LLC | $75.21 | 2023-2024 | Emgality, Amyvid |
| Gilead Sciences, INC. | $64.13 | 2023 | Vemlidy |
| Neurelis, INC. | $47.28 | 2023 | Valtoco |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $39.76 | 2023 | |
| Corium, LLC | $34.67 | 2023 | Adlarity |
| Alexion Pharmaceuticals, INC. | $31.51 | 2023 | Soliris |
| Emd Serono, INC. | $29.82 | 2024 | |
| Idorsia Pharmaceuticals US INC | $29.44 | 2023 | Quviviq |
| Catalyst Pharmaceuticals, INC. | $23.84 | 2023 | Fycompa |
| Amgen INC. | $20.74 | 2023 | Aimovig |
| Acadia Pharmaceuticals INC | $19.51 | 2024 | Nuplazid |
| Kyowa Kirin, INC. | $18.15 | 2023 | Nourianz |
| Impel Pharmaceuticals INC. | $17.21 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dailan Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.